Podocyturia as a possible early marker of renal toxicity during angiogenesis inhibition
Conditions
Interventions
Sixty patients treated with an anti-VEGF monoclonal antibody or RTKI at the department of Oncology of the Amphia hospital will be invited to participate in our study. During a routine visit at the out
Sponsors
Dr. M.H.W. Kappers, Amphia hospital Breda
Eligibility
Inclusion criteria
Inclusion criteria: - Patients with malignancy treated with an anti-VEGF monoclonal antibody or receptor tyrosine kinase inhibitor (RTKI) + chemotherapy - Patients treated with chemotherapy alone (without an anti-VEGF monoclonal antibody or RTKI) = control group 1 - 'Healthy' patients without malignancy and normal kidney function (MDRD > 60 ml/min) without proteinuria (see also exclusion criteria) = control group 2
Exclusion criteria
Exclusion criteria: - Healthy controls (control group 2) with abnormal kidney function and/or proteinuria (protein-to-creatinine ratio > 45 mg/mmol or albumin-to-creatinine ratio > 30 mg/mmol) - Known renal insufficiency (MDRD 45 mg/mmol or albumin-to-creatinine ratio > 30 mg/mmol) if this latter has been previously reported - Previous therapy with an anti-VEGF monoclonal antibody or RTKI - Concomitant chemotherapy frequently associated with renal injury (>10% of patients), e.g. cisplatinum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of podocyturia during treatment with an angiogenesis inhibitor | — |
Secondary
| Measure | Time frame |
|---|---|
| the correlation between podocyturia and proteinuria, the correlation between podocyturia and renal function, the correlation between podocyturia and blood pressure, the effect of angiotensin converting enzyme inhibitors (ACEi) on podocyturia | — |
Contacts
Public ContactKappers
Amphia hospital
Outcome results
None listed